In Brief: ChromaVision
This article was originally published in The Gray Sheet
ChromaVision: Automated microscope systems manufacturer inks exclusive three-year distribution and joint development pact with Sigma Aldrich's Sigma Diagnostics division. Under the terms of the deal, Sigma gains worldwide marketing rights to San Juan Capistrano, California-based ChromaVision's prenatal Down syndrome screening test. The test, which is currently in clinical trials in the U.S. and Great Britain, uses Sigma Diagnostics' reagents and the ChromaVision Dx2000 automated intelligent microscope...
You may also be interested in...
The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.
The advent of COVID-19 and its effects on care delivery have meant that short-term priorities for health care systems have switched temporarily to public health emergency mode. But the longer-term need to restructure delivery around outcomes and federated data management for patients is here to stay, says Royal Philips’ Jeroen Tas.
The pharmaceutical industry is more diverse today in terms of nationality and culture. However, there is still a lack of other types of diversity, which blocks the proactive inclusion of different perspectives. Raafi-Karim Alidina, a consultant with global diversity and inclusion consultancy Frost Included and the co-author of Building An Inclusive Organisation shares his thoughts.